7444 JMed Genet 1996;33:744-748

A recurrent mutation, ala39 1 glu, in the

transmembrane region of FGFR3 causes Crouzon J Med Genet: first published as 10.1136/jmg.33.9.744 on 1 September 1996. Downloaded from syndrome and acanthosis nigricans

D Wilkes, P Rutland, L J Pulleyn, W Reardon, C Moss, J P Ellis, R M Winter, S Malcolm

Abstract and Jackson-Weiss syndromes as an example of Mutations in the fibroblast growth factor the same phenomenon. receptor 2 (FGFR2) gene have previously , which is clinically differ- been identified in Crouzon syndrome, an entiated from these other syndromic forms of autosomal dominant condition involving by the degree of proptosis, premature fusion of the cranial sutures. , and the absence of limb Several different missense and other mu- malformations, has now been associated with tations have been identified in Crouzon over 30 mutations at the FGFR2 locus, syndrome patients, clustering around the missense, splice site, and small in frame third immunoglobulin-like domain. We deletions.4 6 13-15 Mutations are located in both report here the identification of a muta- the first and second half of the third tion in the transmembrane region of immunoglobulin-like domain, and the non- FGFR3, common to three unrelated pa- random pattern of mutations has been dis- tients with classical Crouzon syndrome cussed elsewhere.12 Although the range of and acanthosis nigricans, a dermatologi- FGFR2 mutations associated with Crouzon cal condition associated with thickening syndrome has been broad, the original linkage and abnormal pigmentation of the skin. data showed no evidence of heterogeneity.6 17 The mutation within the FGFR3 tran- To date, analysis of the FGFR2 locus has iden- script was determined by direct sequenc- tified mutations in approximately 66% of our ing as a specific gcg to gag transversion, Crouzon syndrome cohort of 70 patients, none resulting in an amino acid substitution of whom had acanthosis nigricans. ala391glu within the transmembrane re- One of the less common associations seen in gion. a subgroup ofpatients with Crouzon syndrome (37Med Genet 1996;33:744-748) is acanthosis nigricans. This velvety hyperpla- sia of the skin, with accentuation of skin mark- Keywords: Crouzon syndrome; acanthosis nigricans; ings and hyperpigmentation, is usually found http://jmg.bmj.com/ fibroblast 3 (FGFR3). on the neck, axillae, and other flexural regions of the body, but acanthosis nigricans is, in gen- Mothercare Unit of eral, recognised to be clinically heterogeneous. Clinical Genetics and Fetal Medicine and Several clinically distinct monogenic disorders Although uncommon, the association with Molecular Genetics present with craniosynostosis, the premature Crouzon syndrome is clear, 11 such cases hav- of Child Unit, Institute fusion of the skull bone sutures.1 2 Initially ing been identified by Koizumi et al.'8 These

Health, 30 Guilford on September 23, 2021 by guest. Protected copyright. Street, London WClN delineated purely on clinical grounds, several authors drew attention to some atypical lEH,UK reports over the last year have identified the features of the Crouzon associated acanthosis D Wilkes mutational basis of the phenotypes and posed nigricans, specifically the early onset of the P Rutland of L J Pulleyn new questions as to the mechanisms by which pigmentation and the unusual distribution W Reardon the resultant malformations arise.3 Initially the affected skin, particularly involving the R M Winter described in Crouzon syndrome, mutations at perioral region. S Malcolm the fibroblast growth factor receptor 2 Mutations within FGFR3 have been identi- Department of (FGFR2) locus on have since fied in discrete skeletal dysplasias. Four such Dermatology, been identified in Apert and Jackson-Weiss conditions have now been causatively associ- Birmingham syndromes.46 ated with FGFR3 mutations: , Children's Hospital, in Ladywood, A mutation in the related gene on chromo- in which virtually all mutations are the Birmingham B16 8ET, some 8, FGFR1, has been characterised in transmembrane region of the receptor,9-2' UK Pfeiffer syndrome,7 but locus heterogeneity in , in which there are two C Moss this syndrome was established with the obser- mutations in the tyrosine kinase domain,22 23 Department of vation of Pfeiffer syndrome cases having muta- and types I and II Dermatology, Princess tions at the FGFR2 locus.'-" More than three (TDI and II). TDI, in which the femora are Margaret Hospital, such mutations, all resulting in the substitution curved, has been described in association with Okus Road, Swindon, a Wilts SN1 4JU,UK of cys342, have been identified in both missense mutations involving creation of J P Ellis Crouzon and Pfeiffer syndrome cases and the cysteine in the linker region between factors governing the development of these immunoglobulin-like domains 2 and 324 25 and Correspondence to: Dr Reardon. clinically distinct malformation syndromes, read through mutations of the stop codon.26 arising from the same initial mutation, remain Type II, characterised by relatively long and Received 4 March 1996 et have cited an identical straight femora, has been described in associ- Revised version accepted for unclear."2 Gorry all' publication 28 May 1996 mutation (ala344gly) in FGFR2 in Crouzon ation with a tyrosine kinase domain mutation A recurrent mutation, ala391glu, causes Crouzon syndrome and acanthosis nigricans 745

B J Med Genet: first published as 10.1136/jmg.33.9.744 on 1 September 1996. Downloaded from

.. 1: .i. I

1: .i. .: I..k

Figure 1 Postoperative appearance of case 1. Note the mildfacial asymmetry and perioral acanthosis nigricans (A) and theflexural skin thickening and acanthosis nigricans (B). (All photographs reproduced with permission.) (K650E) of FGFR3."4 As both types may be and other clinical parameters were normal. associated with the severe skull malformation, Proptosis and skull malformation were evident clover leaf skull, TDI and II represent evidence from birth and craniosynostosis was confirmed that FGFR3 mutations may also have cranio- radiologically. Motor and intellectual develop- synostosis clinically. We now extend the associ- ment have been normal and the craniosynosto- ation between FGFR3 mutations and cranio- sis has been managed surgically. At the age of synostosis by reporting a single specific 14 years, he was referred to a dermatologist mutation, ala39 1 glu, in the transmembrane (CM) with a history of dry skin on the face region of FGFR3 in three unrelated patients since the age of 9. Clinical examination showed with Crouzon syndrome and acanthosis nigri- extensive acanthosis nigricans of the axilla, http://jmg.bmj.com/ cans. This is only 11 amino acids away, within neck, and, to a lesser extent, the groin. The the transmembrane domain, from the pre- periorbital and perioral skin was prominently dominant mutation causing achondroplasia. affected but there was no palmoplantar or mucosal involvement. There was generalised Patients and methods skin thickening, particularly over the trunk. In CASE 1 addition several small, warty acanthomas were

This male patient (fig 1) was born to clinically noted, as were several melanocytic naevi on the on September 23, 2021 by guest. Protected copyright. normal parents following a normal pregnancy face and upper trunk. and delivery. Birth weight, head circumference,

CASE 2 This female patient was born to clinically nor- mal parents (fig 2). The early clinical course was dominated by problems with feeding and failure to thrive. Incomplete led to associated respiratory difficulties. Her head circumference was on the 50th centile, dispro- portionately large for her height and weight, which were both below the 3rd centile. There was proptosis clinically and skull x ray confirmed premature bicoronal synostosis at the age of 8 months. There was midface hypo- plasia and surgical correction of the craniofa- cial malformations was performed at the age of 10 months. Motor and intellectual develop- ment were normal. Reviewed dermatologically at the age of 6 years (JPE), there was a notable degree of thickening of the skin around the neck and fossae. Velvety thickening and hyper- pigmentation, characteristic of acanthosis nig- ricans, were seen on the neck, axillae, antecu- 746 Wilkes, Rutland, Pulleyn, Reardon, Moss, Ellis, Winter, Malcolm

logical involvement was striking. There were no other abnormalities and a recent blood

sugar evaluation was normal. J Med Genet: first published as 10.1136/jmg.33.9.744 on 1 September 1996. Downloaded from

PCR ANALYSIS DNA was extracted from lymphocytes by salt- ing out.27 Primers amplifying the entire trans- membrane domain of FGFR3 from genomic DNA were used as previously published.9 A 164 bp product results. The primer sequences 5'AGGAGCT- GGTGGAGGCTGA-3' and 5'BioGGAG- ATCTTGTGCACGGTGG-3' were designed to amplify the entire transmembrane domain of FGFR3 from genomic DNA. PCR condi- tions were 200 ng of genomic DNA, 10 mmol.l' Tris, pH 8.3, 1.5 mmol.l1 MgCl, 50 mmol.l' KCI, 200 gmol.l` dNTP, 0.7 !mol l-l c32P-dCTP, 50 pmol of each primer, and 0.5 U Taq polymerase in a final volume of 50 gl: 30 cycles of 94'C x 30 seconds, 64'C x 30 seconds, 72°C x 40 seconds.

RESTRICTION DIGESTION PCR products were purified by phenol/ chloroform ethanol precipitation and restric- Figure 3 Lateral view of case 3 showing tion digestion was performed according to the and maxillary hypoplasia. Note the warty acanthomas over manufacturer's specifications (New England the lower neck (A) and severe acanthosis nigricans over the Biolabs). Resolution of fragment products was neck (B). performed on a 3% agarose gel. bital fossae, and around the umbilicus and the DNA SEQUENCING angles of the mouth. PCR products were sequenced directly by including a single 5' biotinylated primer in the CASE 3 PCR reaction. PCR products were then This 61 year old man was referred for genetic captured and immobilised to Dynabeads counselling for Crouzon syndrome (fig 3). His M280 streptavidin (Dynal). This was followed daughter was also similarly affected with acan- by denaturation using 0.15 mol/l NaOH28 and thosis nigricans. The family history was other- sequencing using oC35S-dATP and the Seque- wise non-contributory. His skull shape had nase (Amersham). http://jmg.bmj.com/ been abnormal from early childhood and surgical reconstruction of his orbits had been Results undertaken at the age of 18 years to reduce his Sequencing showed a point mutation in the proptosis. Skull x ray examination showed patients compared to the normal control and brachycephaly, , and hypoplasia published sequence (fig 4). The C-A mutation of the maxillary bones. He reported the was predicted to destroy a Acil restriction site. presence of acanthosis nigricans from "early The normal fragment sizes generated following on September 23, 2021 by guest. Protected copyright. childhood". Clinical examination showed typi- AczIl digestion of the 164 bp PCR fragment is cal verrucous, hyperpigmented lesions over his 17 bp, 24 bp, 57 bp, and 66 bp while fragment neck, axillae, and groin. There was also hyper- sizes generated following restriction of PCR pigmentation periorbitally and periorally, in products from affected chromosomes of pa- addition to generalised skin thickening and tients were predicted to be 24 bp, 57 bp, and extensive distribution of warty acanthomas 83 bp. Following PCR amplification of the over his back. Being significantly older than affected subjects, products were digested with cases 1 and 2, the progression of his dermato- AczIl and the resulting fragments resolved on a 3% agarose gel (fig 5). All three affected subjects showed the 83 bp fragment while the normal controls showed the wild type restric-

-3 i tion pattern. The parents of case 1 showed the normal wild type pattern, confirming the de novo nature of his mutation. Similarly, the affected daughter of case 3 also shares his mutation. Discussion The data we present confirm that Crouzon syndrome with acanthosis nigricans represents a clinically and genetically distinct subgroup with Crouzon as Figure 4 Sequencing of the transmembrane region of FGFR3. Track 1, wild type. Track 2, among patients syndrome, case 1. reported by Myers et al.29 Together these data, A recurrent mutation, ala391glu, causes Crouzon syndrome and acanthosis nigricans 747

3 2 1 N In keeping with the observations of Koizumi et al'8 in Crouzon syndrome related acanthosis

nigricans, the skin stigmata in our three cases J Med Genet: first published as 10.1136/jmg.33.9.744 on 1 September 1996. Downloaded from 83bp --- showed the atypical age of onset and unusual distribution, including perioral involvement, which seemingly characterises this condition. The phenotype is still unexpected and it remains to be seen whether other Crouzon cases, without the acanthosis nigricans, will be found to have FGFR3 mutations or whether, as might be predicted, the outstanding Crouzon related mutations are located else- where in the FGFR2 gene.

Figure 5 Resolution offragments following PCR This work was funded by the Wellcome Trust and the Medical amplification and restriction digestion with AciI. N: Research Council. normal, 1: case 1, 2: case 2, 3: case 3.

in a total of seven patients, all showing 1 Cohen MM Jr. Craniosynostosis: diagnosis, evaluation and management. New York: Raven, 1986. acanthosis nigricans in addition to Crouzon 2 Winter RM, Baraitser M. The London dysmorphology features, represent the first evidence of locus database. Oxford: Oxford University Press, 1994. 3 Reardon W, Winter RM. The molecular pathology of heterogeneity within the Crouzon syndrome syndromic craniosynostosis Mol Med Today 1995; patient group. That the mutation is causative is 11:432-7. 4 Reardon W, Winter RM, Rutland P, Pulleyn U, Jones BM, confirmed by the de novo observation in case 1 Malcolm S. Mutations in the fibroblast growth factor and the identification of the identical mutation receptor 2 gene cause Crouzon syndrome. Nature Genet in the affected of case 3. 1994;8:98-103. daughter 5 Wilkie AOM, Slaney SF, Oldridge M, et al. The amino acid change, which results in the results from localized mutations of FGFR2 and is allelic with Crouzon Nature substitution of a for a syndrome. Genet 1995;9:165-72. charged non-charged 6 Jabs EW, Li X, Scott AF, et al. Jackson-Weiss and Crouzon residue, is only 11 amino acids away from the syndromes are allelic with mutations in fibroblast growth mutation in the trans- factor receptor 2. Nature Genet 1994;8:275-84. predominant (G380R), 7 Muenke M, Schell U, Hehr A, et al. A commoni mutation in membrane region of FGFR3, found in the fibroblast growth factor receptor 1 gene in Pfeiffer syn- As both mutations involve drome. Nature Genet 1994;8:269-73. achondroplasia. 8 Rutland P, Pulleyn LJ, Reardon W, et al. Identical mutations creation of an additional positive charge, in the FGFR2 gene cause both Pfeiffer and Crouzon syn- correct insertion of the molecule into the drome phenotypes. Nature Genet 1995;9:173-6. 9 Schell U, Hehr A, Feldman GJ, et al. Mutations in FGFR1 membrane is likely to be hindered. and FGFR2 cause familial and sporadic Pfeiffer syn- FGFR3 and FGFR2 have quite different drome. Hum Molec Genet 1995;4:323-8. 10 Lajeunie E, Ma HW, Bonaventure J, Munnich A, Le Merrer patterns of expression during organogeneSiS,31 M, Renier D. FGFR2 mutations in Pfeiffer syndrome. so it is somewhat surprising that mutations in Nature Genet 1995;9:108. 11 Park W, Meyers GA, Li X, et al. Novel FGFR2 mutations in both genes should give rise to such similar Crouzon and Jackson-Weiss syndromes show allelic effects on the sutures of heterogeneity and phenotypic variability. Hum Molec Genet the skull. It further http://jmg.bmj.com/ 1995;4: 1229-33. means that the explanation of the mode of 12 Malcolm S, Reardon W Fibroblast growth factor receptor 2 action should probably include other factors mutations in craniosynostosis. Proc NatlAcad Sci USA (in whose of press). pattern expression reflects more 13 Gorry MG, Preston RA, White GJ, et al. Crouzon closely the tissues affected. Possible candidates syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss are the proteoglycans, which are required as a syndrome. Hum Molec Genet 1995;4:1387-90. third component in the activation of FGFRs by 14 Oldridge M, Wilkie AOM, Slaney SF, et al. Mutations in the FGFs, and whose composition is likely to vary third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Molec on September 23, 2021 by guest. Protected copyright. in different types of cartilage.31 Genet 1995;4: 1077-82. In FGFR3 the 15 Li X, Park W, Pyeritz RE, Jabs EW. Effect on splicing of a general expression pattern is silent FGFR2 mutation in Crouzon syndrome. Nature more restricted than that of FGFR1 and Genet 1995;9:232-3. FGFR2. The most is in 16 Preston RA, Post JC, Keats BJB, et al. A gene for Crouzon prominent expression craniofacial dysostosis maps to the long arm of chromo- prebone cartilage rudiments of all bones some 10. Nature Genet 1994;7:149-53. including flat bones of the skull and later in 17 Li X, Lewanda AF, Eluma F, et al. Two craniosynostotic syndrome loci, Crouzon and Jackson-Weiss, map to chro- development in resting cartilage, a pattern mosome 1 Oq23-q26. Genomics 1994;23:418-24. which correlates well with the skeletal dyspla- 18 Koizumi H, Tomoyori T, Sato KC, Ohkawara A. An associ- ation of acanthosis nigricans and Crouzon syndrome. J sias resulting from several FGFR3 mutations, Dermatol 1992;19:122-6. but is more difficult to explain in cases with 19 Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most only cranial involvement. As with FGFR1 and common genetic form of dwarfism, achondroplasia. Cell 2, the second half of the third 1994;8:335-42. 20 Rousseau F, Bonaventure J, Legeai-Mallet L, et al. immunoglobulin-like loop is encoded by one of Mutations in the gene encoding fibroblast growth factor two alternatively spliced exons. The IlIb form, receptor-3 in achondroplasia. Nature 1994;371:252-4. to KGFR 21 Bellus GA, Hefferon TW, de Luna RIO, et al. Achondro- equivalent in FGFR2, is expressed in plasia is defined by recurrent G380R mutations of mouse skin and epidermal keratinocytes so it FGFR3. Am JtHum Genet 1995;56:368-73. seems that this 22 Bellus GA, McIntosh I, Smith AE, et al. A recurrent muta- likely splice form may be tion in the tyrosine kinase domain of fibroblast growth fac- responsible for the acanthosis nigricans. tor receptor 3 causes hypochondroplasia. Nature Genet As a clinical acanthosis 1995;10:357-9. sign, nigricans is fre- 23 Bellus GA, Sazabo JK, McIntosh L, et al.Hypochondropla- quently observed with syndromes of insulin sia: a second mutation of fibroblast growth factor receptor such as 3 (FGFR3) at nucleotide 1620. Am J Hum Genet resistance, Berardinelli lipodystrophy 1955;57:A47. and mutation involving the 24 Tavormina PL, Shiang R, Thompson LM, et al. Thanato- gene. there is no evidence of dis- phoric dysplasia (types I and II) caused by distinct muta- Significantly, tions in fibroblast growth factor receptor 3. Nature Genet turbed glucose metabolism in any of our cases. 1995;9:321-30. 748 Wilkes, Rutland, Pulleyn, Reardon, Moss, Ellis, Winter, Malcolm

25 Tavormina PL, Rimoin DL, Cohn DH, Zhu Y, Shiang R, sequencing using Dynabeads. Br Haematol 1991;79: Wasmuth JJ. Another mutation that results in the substitu- 113-15. tion of an unpaired cysteine residue in the extracellular 29 Myers GA, Orlow SJ, Munro IR, Prylepa A, Jabs EW.

domain of FGFR3 in thanatophoric dysplasia type I. Hum Fibroblast growth factor receptor 3 (FGFR3) transmem- J Med Genet: first published as 10.1136/jmg.33.9.744 on 1 September 1996. Downloaded from Molec Genet 1995;4:2175-7. brane mutation in Crouzon syndrome with acanthosis nig- 26 Rousseau F, Saugieer P, LeMerrer M, et al. Stop codon ricans. Nature Genet 1995;11:462-4. FGFR3 mutations in thanatophoric dwarfism type I. 30 Peters K, Ornitz DM, Werner S, Williams L. Unique Nature Genet 1995; 10: 11- 12. expression pattern of FGF receptor 3 gene during mouse 27 Miller SA, Dykes DD, Polesky HF. A simple salting out pro- organogenisis. Dev Biol 1995;155:423-30. cedure for extracting DNA from human nucleated cells. 31 Schlessinger J, Lax I, Lemmon M. Regulation of growth Nucleic Acids Res 1988;16:1215. factor activation by proteoglycans: what is the role of low 28 Thein SL, Hinton J. A simple and rapid method of direct affinity receptors. Cell 1995;83:357-60. http://jmg.bmj.com/ on September 23, 2021 by guest. Protected copyright.